Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin™ for β-thalassemia) Gene Therapy Presented at EHA Congress Read more about Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin™ for β-thalassemia) Gene Therapy Presented at EHA Congress
bluebird bio Announces That Its 2020 Annual Meeting of Stockholders Will Be Held in Virtual Format Read more about bluebird bio Announces That Its 2020 Annual Meeting of Stockholders Will Be Held in Virtual Format
Goldman Sachs 41st Annual Global Healthcare Conference Read more about Goldman Sachs 41st Annual Global Healthcare Conference
bluebird bio Announces Live Webcast of EHA Data Review and June Investor Events Read more about bluebird bio Announces Live Webcast of EHA Data Review and June Investor Events
bluebird bio EHA/ASCO Data Review Conference Call Read more about bluebird bio EHA/ASCO Data Review Conference Call
bluebird bio Announces Pricing of Public Offering of Common Stock Read more about bluebird bio Announces Pricing of Public Offering of Common Stock
bluebird bio Announces Proposed Public Offering of Common Stock Read more about bluebird bio Announces Proposed Public Offering of Common Stock
bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual Congress Read more about bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual Congress
Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20 Read more about Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20